Pyrimethamine concentrations in serum during treatment of acute murine experimental toxoplasmosis

Louis M. Weiss, B. J. Luft, H. B. Tanowitz, M. Wittner

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Central nervous system toxoplasmosis is a major opportunistic infection in patients with acquired immunodeficiency syndrome. The standard therapy for this infection is pyrimethamine (PYR) and sulfonamides. To assess in vivo if PYR alone could adequately treat toxoplasmosis, a murine model of acute toxoplasmosis was used. The CD1 strain of mice was infected intraperitoneally with 104 parasites of the RH strain of Toxoplasma gondii. Pyrimethamine was administered in mouse chow at concentrations of 0, 0.03125, 0.0625, 0.125, 0.25, or 1.0 mg of PYR/g of food, which provides the following daily PYR dosages: 0, 6.25, 12.5, 25, 50, and 200 mg/kg/day. No sulfonamides were administered. Serum PYR levels proved more accurate than mg of PYR/g of food in predicting survival. Mice with serum PYR levels ≥ 500 ng/ml (2 μM) survived and had no parasites present on peritoneal lavage. Mice with serum PYR levels < 100 ng/ml (0.4 μM) had a 100% mortality rate and the average parasite count was 3 x 107 organisms in the lavage fluid. At a PYR level of 370 ng/ml, six of 11 mice survived and the lavage fluid contained 2.5 x 105 organisms. Previously, using 3H-uracil in an in vitro assay, PYR at a concentration of 500 ng/ml was shown to be as effective in inhibiting Toxoplasma growth as the combination of PYR (100 ng/ml) and sulfonamides 25 μg/ml). These data suggest the potential usefulness of PYR for monotherapy of toxoplasmosis and are consistent with previously described in vitro assays.

Original languageEnglish (US)
Pages (from-to)288-291
Number of pages4
JournalAmerican Journal of Tropical Medicine and Hygiene
Volume46
Issue number3
StatePublished - 1992

Fingerprint

Pyrimethamine
Toxoplasmosis
Serum
Therapeutics
Sulfonamides
Parasites
Therapeutic Irrigation
Toxoplasma
Cerebral Toxoplasmosis
Peritoneal Lavage
Food
Uracil
Opportunistic Infections

ASJC Scopus subject areas

  • Parasitology
  • Infectious Diseases

Cite this

Pyrimethamine concentrations in serum during treatment of acute murine experimental toxoplasmosis. / Weiss, Louis M.; Luft, B. J.; Tanowitz, H. B.; Wittner, M.

In: American Journal of Tropical Medicine and Hygiene, Vol. 46, No. 3, 1992, p. 288-291.

Research output: Contribution to journalArticle

@article{dfeae4d3702240a688a6f23d7a87c7f8,
title = "Pyrimethamine concentrations in serum during treatment of acute murine experimental toxoplasmosis",
abstract = "Central nervous system toxoplasmosis is a major opportunistic infection in patients with acquired immunodeficiency syndrome. The standard therapy for this infection is pyrimethamine (PYR) and sulfonamides. To assess in vivo if PYR alone could adequately treat toxoplasmosis, a murine model of acute toxoplasmosis was used. The CD1 strain of mice was infected intraperitoneally with 104 parasites of the RH strain of Toxoplasma gondii. Pyrimethamine was administered in mouse chow at concentrations of 0, 0.03125, 0.0625, 0.125, 0.25, or 1.0 mg of PYR/g of food, which provides the following daily PYR dosages: 0, 6.25, 12.5, 25, 50, and 200 mg/kg/day. No sulfonamides were administered. Serum PYR levels proved more accurate than mg of PYR/g of food in predicting survival. Mice with serum PYR levels ≥ 500 ng/ml (2 μM) survived and had no parasites present on peritoneal lavage. Mice with serum PYR levels < 100 ng/ml (0.4 μM) had a 100{\%} mortality rate and the average parasite count was 3 x 107 organisms in the lavage fluid. At a PYR level of 370 ng/ml, six of 11 mice survived and the lavage fluid contained 2.5 x 105 organisms. Previously, using 3H-uracil in an in vitro assay, PYR at a concentration of 500 ng/ml was shown to be as effective in inhibiting Toxoplasma growth as the combination of PYR (100 ng/ml) and sulfonamides 25 μg/ml). These data suggest the potential usefulness of PYR for monotherapy of toxoplasmosis and are consistent with previously described in vitro assays.",
author = "Weiss, {Louis M.} and Luft, {B. J.} and Tanowitz, {H. B.} and M. Wittner",
year = "1992",
language = "English (US)",
volume = "46",
pages = "288--291",
journal = "American Journal of Tropical Medicine and Hygiene",
issn = "0002-9637",
publisher = "American Society of Tropical Medicine and Hygiene",
number = "3",

}

TY - JOUR

T1 - Pyrimethamine concentrations in serum during treatment of acute murine experimental toxoplasmosis

AU - Weiss, Louis M.

AU - Luft, B. J.

AU - Tanowitz, H. B.

AU - Wittner, M.

PY - 1992

Y1 - 1992

N2 - Central nervous system toxoplasmosis is a major opportunistic infection in patients with acquired immunodeficiency syndrome. The standard therapy for this infection is pyrimethamine (PYR) and sulfonamides. To assess in vivo if PYR alone could adequately treat toxoplasmosis, a murine model of acute toxoplasmosis was used. The CD1 strain of mice was infected intraperitoneally with 104 parasites of the RH strain of Toxoplasma gondii. Pyrimethamine was administered in mouse chow at concentrations of 0, 0.03125, 0.0625, 0.125, 0.25, or 1.0 mg of PYR/g of food, which provides the following daily PYR dosages: 0, 6.25, 12.5, 25, 50, and 200 mg/kg/day. No sulfonamides were administered. Serum PYR levels proved more accurate than mg of PYR/g of food in predicting survival. Mice with serum PYR levels ≥ 500 ng/ml (2 μM) survived and had no parasites present on peritoneal lavage. Mice with serum PYR levels < 100 ng/ml (0.4 μM) had a 100% mortality rate and the average parasite count was 3 x 107 organisms in the lavage fluid. At a PYR level of 370 ng/ml, six of 11 mice survived and the lavage fluid contained 2.5 x 105 organisms. Previously, using 3H-uracil in an in vitro assay, PYR at a concentration of 500 ng/ml was shown to be as effective in inhibiting Toxoplasma growth as the combination of PYR (100 ng/ml) and sulfonamides 25 μg/ml). These data suggest the potential usefulness of PYR for monotherapy of toxoplasmosis and are consistent with previously described in vitro assays.

AB - Central nervous system toxoplasmosis is a major opportunistic infection in patients with acquired immunodeficiency syndrome. The standard therapy for this infection is pyrimethamine (PYR) and sulfonamides. To assess in vivo if PYR alone could adequately treat toxoplasmosis, a murine model of acute toxoplasmosis was used. The CD1 strain of mice was infected intraperitoneally with 104 parasites of the RH strain of Toxoplasma gondii. Pyrimethamine was administered in mouse chow at concentrations of 0, 0.03125, 0.0625, 0.125, 0.25, or 1.0 mg of PYR/g of food, which provides the following daily PYR dosages: 0, 6.25, 12.5, 25, 50, and 200 mg/kg/day. No sulfonamides were administered. Serum PYR levels proved more accurate than mg of PYR/g of food in predicting survival. Mice with serum PYR levels ≥ 500 ng/ml (2 μM) survived and had no parasites present on peritoneal lavage. Mice with serum PYR levels < 100 ng/ml (0.4 μM) had a 100% mortality rate and the average parasite count was 3 x 107 organisms in the lavage fluid. At a PYR level of 370 ng/ml, six of 11 mice survived and the lavage fluid contained 2.5 x 105 organisms. Previously, using 3H-uracil in an in vitro assay, PYR at a concentration of 500 ng/ml was shown to be as effective in inhibiting Toxoplasma growth as the combination of PYR (100 ng/ml) and sulfonamides 25 μg/ml). These data suggest the potential usefulness of PYR for monotherapy of toxoplasmosis and are consistent with previously described in vitro assays.

UR - http://www.scopus.com/inward/record.url?scp=0026659769&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026659769&partnerID=8YFLogxK

M3 - Article

C2 - 1558268

AN - SCOPUS:0026659769

VL - 46

SP - 288

EP - 291

JO - American Journal of Tropical Medicine and Hygiene

JF - American Journal of Tropical Medicine and Hygiene

SN - 0002-9637

IS - 3

ER -